Heart failure & cardiomyopathies

Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial

J Am Coll CardiolPublished Randomised crossover trial

Primary result · KCCQ Clinical Summary ScoreResult — go to the resultDifference +4.5 95% CrI 1.3–8.1

Authors' conclusion

In patients with oHCM, RVP delivered at electromechanically optimized AVD improves symptoms and exercise capacity.

Study context

Population
Patients with symptomatic obstructive HCM (resting or provoked LVOT gradient ≥30 mm Hg) with existing dual-chamber devicesrandomized
Participants
60 patients
Comparison
Atrio-ventricular delay (AVD)-optimized right ventricular pacing (RVP) vs backup-only RVP
Primary endpoint
Symptoms by Kansas City Cardiomyopathy Questionnaire Clinical Summary Score
Methodological detailsmulticentre, blinded, Bayesian ordinal mixed modelling, Patients blinded to allocation; symptom assessments self-administered
  • Multicentre
  • Blinded
  • Bayesian ordinal mixed modelling
  • Patients blinded to allocation; symptom assessments self-administered

Primary result

KCCQ Clinical Summary Score

Difference

+4.5

95% CrI 1.3–8.1

As reported in the abstract

Secondary outcomes

OutcomeOR (95% CrI)
Daily symptom scores (ORBITA-app) · CrI; probability of benefit 0.9691.29 (0.98–1.68)
OutcomeDifference (mm Hg) (95% CrI)
LVOT gradient · CrI; probability of benefit 0.010−7.3 (−13.5 to −1.1)
OutcomeDifference (mL/kg/min) (95% CrI)
Exercise capacity · CrI; probability of benefit 0.984+1.0 (0.1–2.0)

B-type natriuretic peptide

No effect on B-type natriuretic peptide (probability of benefit)
0.893

Safety

Ejection fraction

EF preserved (probability of benefit)
0.409

Original publication

Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial. J Am Coll Cardiol. Published 31 August 2025. doi:10.1016/j.jacc.2025.08.050

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.